Overview

This trial is active, not recruiting.

Conditions tetanus, diphtheria, pertussis
Treatments td5ap, td1ap
Phase phase 4
Sponsor Swedish Institute for Infectious Disease Control
Collaborator Sanofi Pasteur MSD
Start date April 2009
End date October 2009
Trial size 400 participants
Trial identifier NCT00870350, 2008-008195-13

Summary

Open-label, randomized, multi-centre study in which 400 subjects, divided into two groups, will receive Td5ap or Td1aP as a single injection. We will then describe the immune response and safety profile of the combined vaccine booster.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose basic science
Arm
(Active Comparator)
Group 1 receiving Td5ap as a single intramuscular injection.
td5ap COVAXiS
Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
(Active Comparator)
Group 2 receiving Td1aP as a single intramuscular injection
td1ap diTekiBooster
Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.

Primary Outcomes

Measure
to describe in each arm the immune response to diptheria toxin, tetanus toxoid, pertussis toxin, FHA, fimbriae 2/3 and pertactin four weeks after immunization with Td1aP and Td5ap
time frame: 42 days

Secondary Outcomes

Measure
safety of a fith dose of DTP vaccines
time frame: 42 days
pre-booster antibody levels
time frame: 42 days
pre-booster and post-booster IgG and IgA levels
time frame: 42 days
pre-booster and post-booster T cell immune responses
time frame: 42 days
pre-booster and post-booster B cell immune responses
time frame: 42 days

Eligibility Criteria

Male or female participants from 14 years up to 15 years old.

Inclusion Criteria: - healthy subject - 14-15 years old - eligible for their school-leaving booster for DTP - received a complete primary vaccination with a 5-component acellular pertussis vaccine (DT5aP-IPV-Hib) at 3, 5 and 12 months of age and vaccinated with a 5-component acellular pertussis vaccine (Td5aP-IPV or Td5aP + IPV) as a booster at 5½ years of age - informed consent form signed by the subject and parent(s)/legal representative - subject understand and comply with the study procedures (i.e. able to read and write Swedish) - female must provide an agreement that they are either sexually continent or practice adequate contraceptive methods (intra-uterine contraceptive device (IUCD), hormonal contraceptives, condoms or other adequate barrier contraception). Exclusion Criteria: - acute febrile illness or axillary temperature ≥38.0°C at the time of vaccination - receipt of immunoglobulin within the previous 3 months, immunosuppression (e g evidence of impaired cell mediated immunity, receipt of immunosuppressant drugs within the previous 3 months or receipt of systemic corticosteroids given daily or on alternate days at ≥20 mg/day prednisone equivalent during >14 days within the past 30 days) - receipt of a non-study vaccine in the past 30 days - evolving encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of any vaccine - booster vaccination with tetanus, low dose diphtheria and acellular pertussis vaccine since the booster vaccination at 5½ years of age - previous clinical or bacteriological diagnosis of diphtheria, tetanus or pertussis - hypersensitivity to any component of any of the study vaccines - current participation in any other clinical trial or participation in any clinical trial in the previous month - inability to adhere to the protocol, including plans to move from the area - severe chronic disease - family history of congenital or hereditary immunodeficiency - any sever thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection - any medical condition, which in the opinion of the investigator, might interfere with the evaluation of the study objectives.

Additional Information

Official title An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age
Principal investigator Leif Gothefors, Prof. em.
Description The vaccines in the study are COVAXIS (Td5ap), Sanofi Pasteur Canada, and diTekiBooster (Td1aP), Statens Serum Institut, Denmark. The primary objective of the study is to describe the immune response to diphtheria toxin, tetanus toxoid, pertussis toxin, filamentous haemagglutinin (FHA), fimbriae 2/3 and pertactin four weeks after immunization with Td1aP and Td5ap. The secondary objectives include: - describing the safety of a fith dose of DTP vaccines in 14-15 year-old children by observing systemic and local adverse reactions - describing pre-booster antibody levels - describing pre-booster and post-booster IgG and IgA levels in saliva - describing in a subpopulation the pre-booster and post-booster T cell immune responses as determined by the production of cytokines - describing in a subpopulation the pre-booster and post-booster B cell immune responses as determined by the number of effector and memory B-cells The sample size is 400 subjects (200 in group 1 and 200 in group 2). It will be an open-label, randomized, multi-centre study in which group 1 will receive Td5ap as a single injection and group 2 will receive Td1aP as a single injection. DTP antibodies will be measured before and 28 days (+ 14 days) after Td5ap and Td1aP vaccination. The proportion of children with positive IgG antibody response will be measured in each study arm. Sera will be tested blindly by established ELISA methods and saliva samples will be analyzed by exploratory assays. In a subpopulation cellmediated immunity will be analyzed. The safety evaluation criteria will be the percentage of subjects with adverse events describing injection-site adverse reactions, systemic adverse events, daily temperatures and serious adverse events.
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by Swedish Institute for Infectious Disease Control.